BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30827939)

  • 1. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.
    Bakouny Z; Flippot R; Braun DA; Lalani AA; Choueiri TK
    Eur Urol Focus; 2020 Jan; 6(1):37-40. PubMed ID: 30827939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
    Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
    Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
    Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
    Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
    Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
    Bedke J; Stühler V; Todenhöfer T; Stenzl A
    Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
    Deleuze A; Saout J; Dugay F; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Crouzet L; Laguerre B; Belaud-Rotureau MA; Rioux-Leclercq N; Kammerer-Jacquet SF
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
    Liu KG; Gupta S; Goel S
    Oncotarget; 2017 Mar; 8(10):17313-17327. PubMed ID: 28061473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches in the therapy of metastatic renal cell carcinoma.
    Lam JS; Leppert JT; Belldegrun AS; Figlin RA
    World J Urol; 2005 Jul; 23(3):202-12. PubMed ID: 15812574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
    Han SC; Yin HQ; Xu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory Therapies for Renal Cell Carcinoma.
    Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
    Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
    Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
    Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
    Raman R; Vaena D
    Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
    Hah YS; Koo KC
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
    Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in kidney cancer: the past, present, and future.
    Hammers H
    Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.